CanSino Biologics Past Earnings Performance
Past criteria checks 0/6
CanSino Biologics's earnings have been declining at an average annual rate of -33.9%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 7.8% per year.
Key information
-33.9%
Earnings growth rate
-32.9%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 7.8% |
| Return on equity | -14.6% |
| Net Margin | -96.2% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How CanSino Biologics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 749 | -720 | 586 | 449 |
| 30 Jun 24 | 635 | -867 | 573 | 486 |
| 31 Mar 24 | 371 | -1,513 | 619 | 585 |
| 31 Dec 23 | 357 | -1,483 | 655 | 638 |
| 30 Sep 23 | 503 | -1,420 | 573 | 691 |
| 30 Jun 23 | 431 | -1,763 | 599 | 793 |
| 31 Mar 23 | 636 | -1,170 | 569 | 771 |
| 31 Dec 22 | 1,035 | -909 | 544 | 778 |
| 30 Sep 22 | 1,921 | 106 | 487 | 772 |
| 30 Jun 22 | 2,868 | 989 | 434 | 651 |
| 31 Mar 22 | 4,332 | 2,050 | 408 | 766 |
| 31 Dec 21 | 4,300 | 1,914 | 329 | 879 |
| 30 Sep 21 | 3,105 | 1,113 | 246 | 908 |
| 30 Jun 21 | 2,082 | 643 | 187 | 872 |
| 31 Mar 21 | 488 | -388 | 103 | 659 |
| 31 Dec 20 | 25 | -397 | 95 | 428 |
| 30 Sep 20 | 6 | -239 | 75 | 234 |
| 30 Jun 20 | 4 | -189 | 64 | 202 |
| 31 Mar 20 | 6 | -135 | 79 | 191 |
| 31 Dec 19 | 2 | -157 | 65 | 152 |
| 30 Sep 19 | 6 | -137 | 66 | 127 |
| 30 Jun 19 | 11 | -156 | 69 | 122 |
| 31 Mar 19 | 9 | -158 | 40 | 89 |
| 31 Dec 18 | 9 | -138 | 46 | 114 |
| 31 Dec 17 | 9 | -64 | 16 | 68 |
| 31 Dec 16 | 8 | -50 | 10 | 52 |
Quality Earnings: CJH is currently unprofitable.
Growing Profit Margin: CJH is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CJH is unprofitable, and losses have increased over the past 5 years at a rate of 33.9% per year.
Accelerating Growth: Unable to compare CJH's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CJH is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: CJH has a negative Return on Equity (-14.61%), as it is currently unprofitable.